Современная стратегия улучшения приверженности лечению больных артериальной гипертонией: фиксированные комбинации лекарственных средств

1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). 2008 г.
2. Шальнова С.А., Балабанова Ю.А., Константинов В.В. и др. Артерильная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–60.
3. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15–8.
4. Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справ. поликлинич. врача. 2007; 6.
5. Pruijm MT, Maillard MP, Burnier M. Приверженность пациентов лечению и выбор антигипертензивной терапии: фокус на лерканидипин. Service of Nephrology and Hypertension, Department of Medicine, University Hospital, Lausanne, Switzerland Источник: Vasc Heal Risk Management 2008; 4 (6): 1159–66.
6. Погосова Г.В., Колтунов И.Е., Мелик-Оганджанян Г.Ю., Соколова О.Ю. Приверженность к лечению сердечно-сосудистых заболеваний: проблема врачей и пациентов. Кардиоваск. тер. и профил. 2009; 4.
7. Garg JP et al. RUSH University Hypertension Service. Am J Hypertens 2005; 18: 619–26.
8. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care 1986; 24: 67–73.
9. Dahlo..f B et al. Prevention of cardiovascular events with with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
10. Advance Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomesin patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
11. Danhlo..f B et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317 (7160): 713–20.
13. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
14. ESH-ESC Guidelines Committee. 2007 guidelines for management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
15. Чазова И.Е., Мартынюк Т.В., Колос И.П. Первые результаты российской программы СТРАТЕГИЯ у пациентов с артериальной гипертензией: оценка эффективности Нолипрела А при недостаточном контроле артериального давления. Cons. Med. 2007; 9.
16. Dahlof B, Gosse Ph, Gueret P et al. Perindopril/Indapamide combination more effective than enelapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063–70.
17. Mourad JJ et al. on behalf of the investigators of the STRATHE trial. Comparision of different therapeutic strategies in hypertension: a low-dose combination of low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004; 22: 2379–96.
18. Mogensen CE et al. Effect of a low dose Perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.
19. PROGRESS collaborative group. Randomised trial of perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
20. Mourad JJ et al. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life? The OPTIMAX study. Eur Heart J 2006; 27 (Suppl.): 298. Abstr 1792.
21. De Luca N et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 8: 660–7.
22. Asmar R, London GM, O’Rourke ME, Safar ME. Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections With a Very-Low-Dose Perindopri/Indapamide Combination in Hypertensive Patient. A Comparisone with Atenolol. Hypertension 2001; 38: 922–6.
23. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new fixed, very-low-dose angiotensineconverting enzyme-inhibitor/diuretic combination as first-line therapy in eldery hypertensive patients. J Hypertens 2000; 18: 327–37.
24. Mourad J-J, Waeber B, Zannad F et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertension 2004; 22: 1–8.
25. Mogensen CE, Viberti G, Halimi S et al. Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. Hypertension 2003; 41: 1063–71.

Т.Е.Морозова, И.Ю.Юдина

ГОУ ВПО Московская медицинская академия им. И. М. Сеченова